Literature DB >> 12709047

Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle.

Annie Husson1, Carole Brasse-Lagnel, Alain Fairand, Sylvie Renouf, Alain Lavoinne.   

Abstract

Argininosuccinate synthetase (ASS, EC 6.3.4.5) catalyses the condensation of citrulline and aspartate to form argininosuccinate, the immediate precursor of arginine. First identified in the liver as the limiting enzyme of the urea cycle, ASS is now recognized as a ubiquitous enzyme in mammalian tissues. Indeed, discovery of the citrulline-NO cycle has increased interest in this enzyme that was found to represent a potential limiting step in NO synthesis. Depending on arginine utilization, location and regulation of ASS are quite different. In the liver, where arginine is hydrolyzed to form urea and ornithine, the ASS gene is highly expressed, and hormones and nutrients constitute the major regulating factors: (a) glucocorticoids, glucagon and insulin, particularly, control the expression of this gene both during development and adult life; (b) dietary protein intake stimulates ASS gene expression, with a particular efficiency of specific amino acids like glutamine. In contrast, in NO-producing cells, where arginine is the direct substrate in the NO synthesis, ASS gene is expressed at a low level and in this way, proinflammatory signals constitute the main factors of regulation of the gene expression. In most cases, regulation of ASS gene expression is exerted at a transcriptional level, but molecular mechanisms are still poorly understood.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12709047     DOI: 10.1046/j.1432-1033.2003.03559.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  92 in total

Review 1.  Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma.

Authors:  N Savaraj; M You; C Wu; M Wangpaichitr; M T Kuo; L G Feun
Journal:  Curr Mol Med       Date:  2010-06       Impact factor: 2.222

2.  Strategies for optimizing the serum persistence of engineered human arginase I for cancer therapy.

Authors:  Everett Stone; Lynne Chantranupong; Candice Gonzalez; Jamye O'Neal; Mridula Rani; Carla VanDenBerg; George Georgiou
Journal:  J Control Release       Date:  2011-10-06       Impact factor: 9.776

3.  Spatial mapping of protein abundances in the mouse brain by voxelation integrated with high-throughput liquid chromatography-mass spectrometry.

Authors:  Vladislav A Petyuk; Wei-Jun Qian; Mark H Chin; Haixing Wang; Eric A Livesay; Matthew E Monroe; Joshua N Adkins; Navdeep Jaitly; David J Anderson; David G Camp; Desmond J Smith; Richard D Smith
Journal:  Genome Res       Date:  2007-01-25       Impact factor: 9.043

4.  Argininosuccinate synthase: at the center of arginine metabolism.

Authors:  Ricci J Haines; Laura C Pendleton; Duane C Eichler
Journal:  Int J Biochem Mol Biol       Date:  2011

5.  Blood pressure follows the kidney: Perinatal influences on hereditary hypertension.

Authors:  Maarten P Koeners; Branko Braam; Jaap A Joles
Journal:  Organogenesis       Date:  2008-07       Impact factor: 2.500

6.  Oncogenic Kaposi's Sarcoma-Associated Herpesvirus Upregulates Argininosuccinate Synthase 1, a Rate-Limiting Enzyme of the Citrulline-Nitric Oxide Cycle, To Activate the STAT3 Pathway and Promote Growth Transformation.

Authors:  Tingting Li; Ying Zhu; Fan Cheng; Chun Lu; Jae U Jung; Shou-Jiang Gao
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

7.  Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis.

Authors:  Randie H Kim; Jodi M Coates; Tawnya L Bowles; Gregory P McNerney; Julie Sutcliffe; Jae U Jung; Regina Gandour-Edwards; Frank Y S Chuang; Richard J Bold; Hsing-Jien Kung
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

8.  Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase.

Authors:  Tawnya L Bowles; Randie Kim; Joseph Galante; Colin M Parsons; Subbulakshmi Virudachalam; Hsing-Jien Kung; Richard J Bold
Journal:  Int J Cancer       Date:  2008-10-15       Impact factor: 7.396

Review 9.  Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes.

Authors:  Macus Tien Kuo; Niramol Savaraj; Lynn G Feun
Journal:  Oncotarget       Date:  2010-08

10.  Pharmacodynamic modeling of acute and chronic effects of methylprednisolone on hepatic urea cycle genes in rats.

Authors:  Anasuya Hazra; Debra C DuBois; Richard R Almon; Grayson H Snyder; William J Jusko
Journal:  Gene Regul Syst Bio       Date:  2008-02-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.